lower schreef op 15 augustus 2017 11:16:
Monoclonal antibody
en.wikipedia.org/wiki/Monoclonal_anti...
Hybridoma development
Monoclonal antibodies are typically made by cell culture that involves fusing myeloma cells with mouse spleen cells immunized with the desired antigen. Rabbit B-cells can be used to form a rabbit hybridoma. Polyethylene glycol is used to fuse adjacent plasma membranes,[4]
Novel mAb development technology
Several monoclonal antibody technologies had been developed recently, such as phage display, single B cell culture,[6] single cell amplification from various B cell populations[7][8][9][10][11] and single plasma cell interrogation technologies.
Human antibodies
Ever since the discovery that monoclonal antibodies could be generated, scientists have targeted the creation of "fully" human products to reduce the side effects of humanised or chimeric antibodies. Two successful approaches have been identified: transgenic mice[21] and phage display.
Seven of the nine "fully" human monoclonal antibody therapeutics on the market were derived from transgenic mice technology.[22]
Adopting organizations who market transgenic technology include:
Medarex — which marketed the UltiMab platform. Medarex was acquired in July 2009 by Bristol Myers Squibb[23]
Abgenix — which marketed the Xenomouse technology. Abgenix was acquired in April 2006 by Amgen.[24]
Regeneron's VelocImmune technology.[25]
Kymab - who market their Kymouse technology.[26]
Open Monoclonal Technology's OmniRat™ and OmniMouse™ platform.[27]
TRIANNI, Inc. – who market their TRIANNI Mouse platform.[28]
Phage display can be used to express variable antibody domains on filamentous phage coat proteins (Phage major coat protein).[29][30][31] These phage display antibodies can be used for various research applications.[32][33] ProAb was announced in December 1997[34] and involved high throughput screening of antibody libraries against diseased and non-diseased tissue, whilst Proximol used a free radical enzymatic reaction to label molecules in proximity to a given protein.[35][36]
Monoclonal antibodies have been approved to treat cancer, cardiovascular disease, inflammatory diseases, macular degeneration, transplant rejection, multiple sclerosis and viral infection.
In August 2006 the Pharmaceutical Research and Manufacturers of America reported that U.S. companies had 160 different monoclonal antibodies in clinical trials or awaiting approval by the Food and Drug Administration.[37]
August 12, 2015 Rentschler is responsible for providing cGMP drug substance of DX-2930 for Dyax Corp.
www.rentschler.de/news/press-releases...Both DX-2930 and KALBITOR were identified using Dyax's proprietary phage display technology.
Phage display
en.wikipedia.org/wiki/Phage_display